Erythropoiesis-stimulating agents for anemic patients with cancer

References

• Groopman JE. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl Cancer Inst.91, 1616–1634, (1999).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P et al. The European cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur. J. Cancer40, 2293–2306, (2004).
   PubMed Web of Science ®Google Scholar
• Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist14(Suppl. 1), 43–56 (2009).
   PubMed Web of Science ®Google Scholar
• Wood PA, Hrushesky WJM. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J. Clin. Invest.95(4), 1650–1659 (1995).
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brilliant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet373, 1532–1542 (2009).
   PubMed Web of Science ®Google Scholar
• Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann. Oncol.15(6), 979–986 (2004).
   PubMed Web of Science ®Google Scholar
• Lind M, Vernon C, Cruikshank D et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br. J. Cancer86(8), 1243–1249 (2002).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer91(12), 2214–2221 (2001).
   PubMed Web of Science ®Google Scholar
• Dubsky P, Sevelda P, Jakesz R et al. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin. Cancer Res.14(7), 2082–2087 (2008).
   PubMed Web of Science ®Google Scholar
• Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist12(Suppl. 3), 21–26 (2008).
   Google Scholar
• Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist5(5), 353–360 (2000).
   PubMedGoogle Scholar
• Glaus A, Mueller S. Hemoglobin and fatigue in cancer patients: inseparable twins? Schweiz. Med. Wochenschr.130, 471–477 (2000).
   PubMedGoogle Scholar
• Spano JP, Khayat D. Treatment options for anaemia, taking risks into consideration: erythopoiesis-stimulating agents versus transfusions. Oncologist12(Suppl.3), 27–32 (2008).
   Google Scholar
• Surgenor SD, Kramer RS, Olmstead EM et al. The association of per-operative red blood cell transfusions and decreased long-term survival after cardiac survival. Anesth. Anal.108, 1741–1746 (2009).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Fritz E, Kotzmann H, Hoecker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med.322(24), 1693–1699 (1990).
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brilliant C et al. Erythropoietin or darbepoetin for patients with cancer – meta-analysis based on individual patient data. Cochrane Database Syst. Rev.3, 1–289 (2009).
   Google Scholar
• Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin. J. Am. Soc. Nephrol.3(1), 200–207 (2008).
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Rossert J, Casadevall N et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N. Engl. J. Med.361(19), 1848–1855 (2009).
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JWR et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol.19(11), 2865–2874 (2001).
   PubMed Web of Science ®Google Scholar
• Wolson J, Yao GL, Raftery J et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess.11(13), 1–202 (2007).
   Google Scholar
• Jadersten M, Malcovati L, Dybedal I et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J. Clin. Oncol.26, 3607–3613 (2008).
   PubMed Web of Science ®Google Scholar
• Baron F, Frere P, Beguin Y. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica88, 718–720 (2003).
   PubMed Web of Science ®Google Scholar
• Vanstraelen G, Baron F, Frere P, Hafraoui K, Fillet G, Beguin Y. Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica90, 1269–1270 (2005).
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CD, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol.19(11), 2875–2882 (2001).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Beguin Y, Kloczo J, Spicka I, Coiffier B. Once-weekly epoietin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br. J. Haematol.122(3), 386–393 (2003).
   PubMed Web of Science ®Google Scholar
• Chang J, Couture F, Young S et al. Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol.23(12), 2597–2605 (2005).
   PubMed Web of Science ®Google Scholar
• Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J. Clin. Oncol.23(12), 2606–2617 (2005).
   PubMed Web of Science ®Google Scholar
• Theurl I, Aigner E, Theurl M et al. Regulation of iron haemostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood113, 5277–5286 (2009).
   PubMed Web of Science ®Google Scholar
• Locatelli F, Gascon P. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks. Oncologist14(Suppl. 1), 57–62 (2009).
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H. Intravenous iron in oncology. J. Natl Compr. Canc. Netw.6(6), 585–592 (2008).
   PubMedGoogle Scholar
• Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol.22(7), 1301–1307 (2004).
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist12(2), 231–242 (2007).
   PubMed Web of Science ®Google Scholar
• Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies. Leukemia21(4), 627–632 (2007).
   PubMed Web of Science ®Google Scholar
• Bastit L, Vandebroek A, Altintas S et al. A randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administration every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol.25(10), 1611–1618 (2008).
   Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J. Clin. Oncol.25(10), 1619–1625 (2008).
   Web of Science ®Google Scholar
• Steensma DP, Dakhil SR, Dalton R et al. A Phase III randomised study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia; a study of the Mayo Clinic Research Consortium (MCCRC). Presented at: 51st American Society of Haematology. New Orleans, LA, USA, 5–8 December 2009 (Abstract 630).
   Google Scholar
• Auerbach M. Should intravenous iron be the standard of care in oncology? J. Clin. Oncol.26(10), 1579–1581 (2008).
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Alikhan R. The use of intravenous iron in patients with cancer-related anaemia. Br. J. Haematol.141(6), 751–756 (2008).
   PubMed Web of Science ®Google Scholar
• Bunn HF. End run around Epo. N. Engl. J. Med.361(19), 1901–1903 (2009).
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Zagari M, Pallister C et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist8(1), 99–107 (2003).
   PubMed Web of Science ®Google Scholar
• Reinhardt U, Tulusan A, Angermund R et al. Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicentre German trial. Oncologist10(3), 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Seidenfeld J, Piper M, Aronson N, Lichtin A, Littlewood TJ. Erythropoietin: a paradigm for the development of practice guidelines. Hematology Am. Soc. Hematol. Educ. Program1, 10–30 (2001).
   Google Scholar
• Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol.16(10), 3412–3425 (1998).
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol.15(3), 1218–1234 (1997).
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Gagnon D, Zagari M et al. Multivariate regression analyses of data from a randomized, double-blind, placebo-controlled study confirm quality of life benefit from epoetin alfa in patients receiving non-platinum chemotherapy. Br. J. Cancer87(12), 1341–1353 (2002).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl Cancer Inst.94, 1211–1220 (2002).
   PubMed Web of Science ®Google Scholar
• Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys.50(3), 705–715 (2001).
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Ruebe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet362, 1255–1260 (2003).
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol.23(25), 5960–5972 (2005).
   PubMed Web of Science ®Google Scholar
• Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol.25(9), 1027–1032 (2007).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoietin administration for the treatment of cancer-associated anemia. JAMA299(8), 914–924 (2008).
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen EA, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoietin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin. Ther.28(6), 801–822 (2006).
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev.1, 1–273 (2006).
   Google Scholar
• Aapro M, Spivak JL. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist14(Suppl. 1), 6–15 (2009).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anaemia. J. Clin. Oncol.27, 1–10 (2009).
   PubMedGoogle Scholar
• Fandrey J, Dicato M. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist14(Suppl. 1), 34–42 (2009).
   PubMed Web of Science ®Google Scholar
• Littlewood TJ. Is normalising haemoglobin in patients with CKD harmful and if so why? J. Renal Care35, 25–28 (2009).
   PubMedGoogle Scholar
• Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J. Clin. Oncol.24(29), 4708–4713 (2006).
   PubMed Web of Science ®Google Scholar
• Arcasoy MO. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin. Cancer Res.14(15), 4685–4690 (2008).
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Todd MD, Forsythe K et al. Expression and function of erythropoietin receptors in tumors. Cancer110(3), 477–488 (2007).
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Coxon A, McCaffery I et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal and renal cells. Blood115, 4264–4272 (2010).
   PubMed Web of Science ®Google Scholar
• Swift S, Ellison AR, Kassner P et al. Absence of functional EpoR expression in human tumour cell lines. Blood115, 4254–4263 (2010).
   PubMed Web of Science ®Google Scholar
• Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N. Engl. J. Med.356(24), 2445–2448 (2007).
   PubMed Web of Science ®Google Scholar
• Steinbrook R. Erythropoietin, the FDA, and oncology. N. Engl. J. Med.356(24), 2448–2451 (2007).
   PubMed Web of Science ®Google Scholar
• Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol.9(2), 81 (2008).
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Erythropoietin: back to basics. Blood115, 4151–4152 (2010)
   PubMed Web of Science ®Google Scholar
• Sasu BJ, Cooke KS, Arvedson TL et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood115, 3616–3624 (2010).
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J. Clin. Oncol.26, 132–149 (2008).
   PubMed Web of Science ®Google Scholar